Yeh S-A, Ho J-T, Lui C-C, Huang Y-J, Hsiung C-Y, Huang E-Y
Department of Radiation Oncology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Br J Radiol. 2005 Mar;78(927):230-5. doi: 10.1259/bjr/28534346.
Low-grade gliomas account for 10-15% of all adult primary intracranial tumours. Currently, there is no consensus on the treatment strategy for low-grade gliomas. This study was designed to evaluate the treatment outcomes, prognostic factors and radiation-related late complications, as well as to assess whether or not post-operative radiotherapy has benefit on local control and overall survival in this population. We retrospectively reviewed 93 consecutive adult patients with supratentorial low-grade gliomas diagnosed at our institution from July 1985 to December 1997. All patients underwent surgical intervention and 60 of them received post-operative radiotherapy. With a median follow-up of 110 months for surviving patients, the 5-year overall and progression-free survival rates were 57% and 47%, respectively. 46 patients experienced local progression of disease during the follow-up period. In multivariate analysis, age at diagnosis, extent of surgery and post-operative Karnofsky performance status showed independent prognostic significance for progression-free and overall survival rates. Post-operative radiotherapy had independent prognostic value for progression-free survival. This analysis has changed our practice and we suggest that aggressive surgical resection and post-operative radiotherapy might be considered for patients with low-grade gliomas. Further efforts should be made to optimize radiotherapy techniques and to integrate new therapeutic modalities.
低级别胶质瘤占所有成人原发性颅内肿瘤的10%-15%。目前,对于低级别胶质瘤的治疗策略尚无共识。本研究旨在评估治疗效果、预后因素及放疗相关的晚期并发症,以及评估术后放疗对该人群局部控制和总生存期是否有益。我们回顾性分析了1985年7月至1997年12月在我院确诊的93例连续性幕上低级别胶质瘤成年患者。所有患者均接受了手术干预,其中60例接受了术后放疗。存活患者的中位随访时间为110个月,5年总生存率和无进展生存率分别为57%和47%。46例患者在随访期间出现疾病局部进展。多因素分析显示,诊断时年龄、手术范围及术后卡氏评分对无进展生存率和总生存率具有独立的预后意义。术后放疗对无进展生存率具有独立的预后价值。该分析改变了我们的治疗实践,我们建议对于低级别胶质瘤患者可考虑积极的手术切除及术后放疗。应进一步努力优化放疗技术并整合新的治疗模式。